156 related articles for article (PubMed ID: 9296893)
21. Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
Henkel E; Gallo S; Siegert G; Koehler C; Hanefeld M
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):327-34. PubMed ID: 17473573
[TBL] [Abstract][Full Text] [Related]
22. [Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in children with ulcerative colitis].
Grabarczyk E; Szaflarska-Popławska A; Góralczyk K; Rość D
Pol Merkur Lekarski; 2006 Mar; 20(117):326-8. PubMed ID: 16780267
[TBL] [Abstract][Full Text] [Related]
23. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
24. Effect of nonionic and ionic contrast media on fibrinolysis in patients undergoing angiography.
Giedrojć J; Radziwon P; Krupiński K; Kiełpińska K; Galar M; Bielawiec M
Pol J Pharmacol; 1996; 48(3):323-6. PubMed ID: 9112670
[TBL] [Abstract][Full Text] [Related]
25. Tissue plasminogen activator and its inhibitor following major surgery in relation to ventilatory pattern.
Eriksson E; Risberg B
Acta Chir Scand; 1988 Jan; 154(1):57-60. PubMed ID: 3128033
[TBL] [Abstract][Full Text] [Related]
26. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
27. [Fibrinolytic system in bronchial asthma after prednisone treatment].
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Pol Merkur Lekarski; 2000 Jan; 7(43):9-11. PubMed ID: 10765644
[TBL] [Abstract][Full Text] [Related]
28. Prospective double-arm study of fibrinolysis in surgical patients.
Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
[TBL] [Abstract][Full Text] [Related]
29. Sex differences in the determinants of fibrinolytic activity.
MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
Buduneli N; Buduneli E; Ciotanar S; Atilla G; Lappin D; Kinane D
J Clin Periodontol; 2004 Jul; 31(7):556-61. PubMed ID: 15191592
[TBL] [Abstract][Full Text] [Related]
31. Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
Mansfield MW; Catto AJ; Carter AM; Grant PJ
Diabet Med; 1998 Nov; 15(11):953-7. PubMed ID: 9827850
[TBL] [Abstract][Full Text] [Related]
32. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
34. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis.
Páramo JA; Alfaro MJ; Rocha E
Thromb Haemost; 1985 Oct; 54(3):713-6. PubMed ID: 3937269
[TBL] [Abstract][Full Text] [Related]
35. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
36. Tissue plasminogen activator (t-PA) and placental plasminogen activator inhibitor (PAI-2) in gingival crevicular fluid from patients with Papillon-Lefèvre syndrome.
Ullbro C; Kinnby B; Lindberg P; Matsson L
J Clin Periodontol; 2004 Sep; 31(9):708-12. PubMed ID: 15312091
[TBL] [Abstract][Full Text] [Related]
37. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
[TBL] [Abstract][Full Text] [Related]
38. A kinetic model of the circulatory regulation of tissue plasminogen activator during orthotopic liver transplantation.
Crookston KP; Marsh CL; Chandler WL
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):79-88. PubMed ID: 10691102
[TBL] [Abstract][Full Text] [Related]
39. The fibrinolytic system in chronic renal failure.
Lottermoser K; Petras S; Pöge U; Fimmers R; Hertfelder HJ; Schiermeyer B; Vetter H; Düsing R
Eur J Med Res; 2001 Sep; 6(9):372-6. PubMed ID: 11591527
[TBL] [Abstract][Full Text] [Related]
40. Tissue-type plasminogen activator in patients with intracranial meningiomas.
Tsuda H; Oka K; Noutsuka Y; Sueishi K
Thromb Haemost; 1988 Dec; 60(3):508-13. PubMed ID: 3149049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
